Bortezomib
- Product NDC
- 70860-225
- 11-digit product format
- 708600225
- Labeler code
- 70860
- Product ID
- 70860-225_49aeb918-1016-4748-aa7a-53c51014e650
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- bortezomib
- Dosage form
- INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
- Route
- INTRAVENOUS; SUBCUTANEOUS
- Labeler
- Athenex Pharmaceutical Division, LLC.
- Application
- ANDA210824
- Marketing category
- ANDA
- Marketing start
- 2022-05-06
- Marketing end
- 0000-00-00
- Substance
- BORTEZOMIB
- Active strength
- 4 mg/1
- Pharmacologic classes
- Proteasome Inhibitor [EPC], Proteasome Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
FDA-Initiated Inactive NDC Indexing#
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 70860-225-10 | 70860022510 | 1 VIAL, SINGLE-DOSE in 1 CARTON (70860-225-10) > 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE | 2022-05-06 | 0000-00-00 | No | No | Current |